<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cyclooxygenase-2 (COX-2) is reported to be an important cellular target for therapy in <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The growth inhibitory effects of COX-2 inhibitors on <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> have been demonstrated to be through not only COX-2 dependent, but also independent mechanisms </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we showed that etodolac, COX-2 inhibitor, induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> via COX-2 independent pathway, and investigated the molecular details of etodolac-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells </plain></SENT>
<SENT sid="3" pm="."><plain>In Daudi and Raji Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell lines, which expressed no COX-2 enzyme, etodolac more strongly induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> compared to meloxicam </plain></SENT>
<SENT sid="4" pm="."><plain>Moreover, etodolac did not induce <z:mpath ids='MPATH_3'>apoptosis</z:mpath> to <z:mpath ids='MPATH_458'>normal</z:mpath> B-lymphocytes </plain></SENT>
<SENT sid="5" pm="."><plain>For the pathway of etodolac-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, reduction of anti-apoptotic bcl-2 mRNA and Bcl-2 protein, activation of Caspase-9 and -3, down-regulation of caspase inhibitors, c-IAP-1 and Survivin were involved </plain></SENT>
<SENT sid="6" pm="."><plain>Moreover, EBER-1 and -2 expression in Epstein-Barr virus positive Daudi and Raji cells were reduced to result in down-regulation of Bcl-2 by treatment with etodolac </plain></SENT>
<SENT sid="7" pm="."><plain>It has been reported that etodolac has stereoisomers, R- and S-etodolac </plain></SENT>
<SENT sid="8" pm="."><plain>We found that racemate of etodolac more strongly induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in Daudi and Raji cells compared to R- or S-etodolac </plain></SENT>
<SENT sid="9" pm="."><plain>In conclusion, our findings indicated etodolac inhibited EBERs expression and induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> via a Bcl-2-regulated pathway </plain></SENT>
<SENT sid="10" pm="."><plain>Moreover, racemate of etodolac more effectively induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> than R- and/or S-etodolac </plain></SENT>
<SENT sid="11" pm="."><plain>Therefore, these activities of etodolac potentially extend to the treatment of patients with Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> resistant to chemotherapy </plain></SENT>
</text></document>